Alper Biotech is a biotechnology company specializing in the development and commercialization of monoclonal antibodies. These antibodies are used to detect cancer-cell specific and soluble biomarkers in one drop of blood for early diagnosis of solid-tumor cancers.
Alper Biotech uses a proprietary, patent pending technology in developing these antibodies. This technology produces monoclonal antibodies with the highest sensitivity and specificity to identify soluble biomarkers.
Alper Biotech monoclonal antibodies are developed for research, diagnostic and therapeutic applications. Alper technology delivers monoclonal antibodies with the highest affinity for the biomarkers that they are raised for.
Dr. Alper has been involved in molecular oncology for over 20 years and is recognized by her peers as a leading researcher in the field of cancer biology, diagnosis and therapy. She holds degrees from Hacettepe University and the prestigious Tokyo University.
Prior to launching Alper Biotech, Dr. Alper was affiliated and served in a number of different capacities with the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).
Dr. Alper was awarded the Princess Takamatsu Foundation for the Promotion of Cancer Research as a result of showing for the first time, that HER-2, an EGFR supergene family member, is secreted from breast cancer cells. Secreted HER-2 has been associated with aggressive clinical progression of breast cancers and is a serum marker for metastatic breast cancers.
Sign In
View Cart
Help Desk
